Program
PIPE-791
A development code. Also written as “PIPE-791 Dose A” and “PIPE-791 Dose B”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Chronic Pain · Multiple Sclerosis, led by Contineum Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Contineum Therapeutics | 41 open or running | phase 2since Dec 8, 2025 | Jul 19, 2023 | May 2028phase 2 · NCT07284459 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 19, 2023First study: phase 1 study in Multiple SclerosisFirst studyNCT05983939 · 56 enrolled · United States
- Nov 6, 2024Phase 1 study in Idiopathic Pulmonary FibrosisNCT06683612 · 16 enrolled · United Kingdom
- Jan 22, 2025Phase 1 study in Chronic PainNCT06810245 · 43 enrolled · United States
- Dec 8, 2025Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07284459 · 324 planned · Argentina, Australia, Belgium and more
Ahead
- May 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07284459
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07284459Idiopathic Pulmonary Fibrosis · Argentina, Australia, Belgium and more | 2 | Recruiting | May 2028 | 324 |
| NCT06810245Chronic Pain · United States | 1 | Completed | Jan 20, 2026 | 43 |
| NCT06683612Idiopathic Pulmonary Fibrosis · United Kingdom | 1 | Completed | Jun 4, 2025 | 16 |
| NCT05983939Multiple Sclerosis · United States | 1 | Completed | Feb 1, 2024 | 56 |
How it is read
Names in the registry
- “PIPE-791”, 3 entries
- “PIPE-791 Dose A”, 1 entry
- “PIPE-791 Dose B”, 1 entry
Codes read as this program: PIPE791.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 2 studies
- Chronic Pain, 1 study
- Multiple Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.